Abstract
Anxiety disorders are highly prevalent psychiatric diseases1,2. There is need for a deeper understanding of anxiety control mechanisms in the mammalian brain and for development of new anxiolytic agents. Here we report that the coupling between neuronal nitric oxide synthase (nNOS) and its carboxy-terminal PDZ ligand (CAPON) can serve as a target for developing new anxiolytic agents. Augmenting nNOS-CAPON interaction in the hippocampus of mice by overexpressing full-length CAPON gave rise to anxiogenic-like behaviors, whereas dissociating CAPON from nNOS by overexpressing CAPON-125C or CAPON-20C (the C-terminal 125 or 20 amino acids of CAPON) or delivering Tat-CAPON-12C (a peptide comprising Tat and the 12 C-terminal amino acids of CAPON) in the hippocampus of mice produced anxiolytic-like effects. Mice subjected to chronic mild stress (CMS) displayed a substantial increase in nNOS-CAPON coupling in the hippocampus and a consequent anxiogenic-like phenotype. Disrupting nNOS-CAPON coupling reversed the CMS-induced anxiogenic-like behaviors. Moreover, small-molecule blockers of nNOS-CAPON binding rapidly produced anxiolytic-like effects. Dexamethasone-induced ras protein 1 (Dexras1)–extracellular signal–regulated kinase (ERK) signaling was involved in the behavioral effects of nNOS-CAPON association. Thus, nNOS-CAPON association contributes to the modulation of anxiety-related behaviors via regulating Dexras1-ERK signaling and can serve as a target for developing potential anxiolytics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Kessler, R.C. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593–602 (2005).
Tye, K.M. et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471, 358–362 (2011).
Rupprecht, R. et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490–493 (2009).
Zhou, Q.G. et al. Hippocampal neuronal nitric oxide synthase mediates the stress-related depressive behaviors of glucocorticoids by downregulating glucocorticoid receptor. J. Neurosci. 31, 7579–7590 (2011).
Reif, A. et al. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol. Psychiatry 11, 286–300 (2006).
Nelson, R.J. et al. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 378, 383–386 (1995).
Zhang, J. et al. Neuronal nitric oxide synthase alteration accounts for the role of 5–HT1A-receptor in modulating anxiety-related behaviors. J. Neurosci. 30, 2433–2441 (2010).
Fang, M. et al. Dexras1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. Neuron 28, 183–193 (2000).
Zhou, L. et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med. 16, 1439–1443 (2010).
Jaffrey, S.R., Snowman, A.M., Eliasson, M.J., Cohen, N.A. & Snyder, S.H. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 20, 115–124 (1998).
Carrel, D. et al. NOS1AP regulates dendrite patterning of hippocampal neurons through a carboxypeptidase E–mediated pathway. J. Neurosci. 29, 8248–8258 (2009).
Richier, L. et al. NOS1AP associates with Scribble and regulates dendritic spine development. J. Neurosci. 30, 4796–4805 (2010).
Lawford, B.R. et al. NOS1AP is associated with increased severity of PTSD and depression in untreated combat veterans. J. Affect. Disord. 147, 87–93 (2013).
Cheng, H.Y. et al. The molecular gatekeeper Dexras1 sculpts the photic responsiveness of the mammalian circadian clock. J. Neurosci. 26, 12984–12995 (2006).
Mogha, A., Guariglia, S.R., Debata, P.R., Wen, G.Y. & Banerjee, P. Serotonin 1A receptor–mediated signaling through ERK and PKCα is essential for normal synaptogenesis in neonatal mouse hippocampus. Transl. Psychiatry 2, e66 (2012).
Giachello, C.N. et al. MAPK/Erk-dependent phosphorylation of synapsin mediates formation of functional synapses and short-term homosynaptic plasticity. J. Cell Sci. 123, 881–893 (2010).
Duman, R.S. & Aghajanian, G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 338, 68–72 (2012).
Duric, V. et al. A negative regulator of MAP kinase causes depressive behavior. Nat. Med. 16, 1328–1332 (2010).
Xu, B. et al. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med. 2, e263 (2005).
Brzustowicz, L.M. NOS1AP in schizophrenia. Curr. Psychiatry Rep. 10, 158–163 (2008).
Tochio, H., Zhang, Q., Mandal, P., Li, M. & Zhang, M. Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat. Struct. Biol. 6, 417–421 (1999).
Schwarze, S.R., Ho, A., Vocero-Akbani, A. & Dowdy, S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569–1572 (1999).
Martinowich, K., Manji, H. & Lu, B. Mew insights into BDNF function in depression and anxiety. Nat. Neurosci. 10, 1089–1093 (2007).
Parihar, V.K., Hattiangady, B., Kuruba, R., Shuai, B. & Shetty, A.K. Predictable chronic mild stress improves mood, hippocampal neurogenesis and memory. Mol. Psychiatry 16, 171–183 (2011).
Pucilowska, J., Puzerey, P.A., Karlo, J.C., Galán, R.F. & Landreth, G.E. Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuron-cardio- facial-cutaneous and related syndromes. J. Neurosci. 32, 8663–8677 (2012).
Hu, Y. et al. Hippocampal nitric oxide contributes to sex difference in affective behaviors. Proc. Natl. Acad. Sci. USA 109, 14224–14229 (2012).
Soetanto, A. et al. Association of anxiety and depression with microtubule-associated protein 2- and synaptopodin-immunolabeleddendrite and spine densities in hippocampal CA3 of older humans. Arch. Gen. Psychiatry 67, 448–457 (2010).
Mucha, M. et al. Lipocalin-2 controls neuronal excitability and anxiety by regulating dendrtitic spine formation and maturation. Proc. Natl. Acad. Sci. USA 108, 18436–18441 (2011).
Lonetti, G. et al. Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol. Psychiatry 67, 657–665 (2010).
Kao, H.T. et al. A third member of the synapsin gene family. Proc. Natl. Acad. Sci. USA 95, 4667–4672 (1998).
Ryan, X.P. et al. The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. Neuron 47, 85–100 (2005).
Xu, J.Y. & Sastry, B.R. Benzodiazepine involvement in LTP of the GABA-ergic IPSC in rat hippocampal CA1 neurons. Brain Res. 1062, 134–143 (2005).
Feyder, M. et al. Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome. Am. J. Psychiatry 167, 1508–1517 (2010).
Jaffrey, S.R., Benfenati, F., Snowman, A.M., Czernik, A.J. & Snyder, S.H. Neuronal nitric-oxide synthase localization mediated by a ternary complex with synapsin and CAPON. Proc. Natl. Acad. Sci. USA 99, 3199–3204 (2002).
Chang, K.C. et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc. Natl. Acad. Sci. USA 105, 4477–4482 (2008).
Munoz, J.R., Stoutenger, B.R., Robinson, A.P., Spees, J.L. & Prockop, D.J. Human stem progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl. Acad. Sci. USA 102, 18171–18176 (2005).
Fanselow, M.S. & Dong, H.W. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65, 7–19 (2010).
Rudolph, U. et al. Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes. Nature 401, 796–800 (1999).
Bonetti, E.P. et al. Benzodiazepine antagonist RO 15–1788: neurological and behavioral effects. Psychopharmacology (Berl.) 78, 8–18 (1982).
Ren, L. et al. GABAA receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem. Pharmacol. 79, 1337–1344 (2010).
Stricker, N.L. et al. PDZ domain of neuronal nitric oxide synthase recognizes novel C-terminal peptide sequences. Nat. Biotechnol. 15, 336–342 (1997).
Doyle, D.A. et al. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85, 1067–1076 (1996).
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (91232304, 81222016, 81030023 and 21303086), the National Basic Research Program of China (973 Program) (2011CB504404) and the Natural Science Foundation of Jiangsu Province–Special Program grant BK2011029 and Distinguished Young Scientist Fund BK20130040, and by the Collaborative Innovation Center For Cardiovascular Disease Translational Medicine. We thank X.D. Qian, H.Y. Ni, F.Y. Zhang, Y. Hu, Y. Tang and Z. Zhu for technical assistance.
Author information
Authors and Affiliations
Contributions
L.-J.Z. and C.C. performed the cell culture studies, coimmunoprecipitation, western blotting, surgical preparation and animal behavioral examinations. T.-Y.L. and L.C. contributed the design and synthesis of small-molecule compounds. Y.Z. and H.-H.Z. contributed recombinant lentivirus production and Tat-CAPON-12C preparation. N.J. performed molecular dynamics simulations, interaction energy calculations and force field parameterization for ZLc-002. C.-X.L. contributed to the design of the study. W.L. performed electrophysiological experiments. L.-Y.G., Y.-H.L., Y.M., Q.-G.Z., J.Z. and H.-Y.W. participated in the study. Q.H. and X.-L.H. analyzed concentrations of ZLc-002 and its metabolites. D.-Y.Z. initiated the project, designed the study and wrote the paper. All authors contributed to data analysis.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–10, Supplementary Tables 1–5, Supplementary Methods and Supplementary Discussion (PDF 2359 kb)
Rights and permissions
About this article
Cite this article
Zhu, LJ., Li, TY., Luo, CX. et al. CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med 20, 1050–1054 (2014). https://doi.org/10.1038/nm.3644
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3644
This article is cited by
-
nNOS in Erbb4-positive neurons regulates GABAergic transmission in mouse hippocampus
Cell Death & Disease (2024)
-
Enhanced AMPAR-dependent synaptic transmission by S-nitrosylation in the vmPFC contributes to chronic inflammatory pain-induced persistent anxiety in mice
Acta Pharmacologica Sinica (2023)
-
Hippocampus: Molecular, Cellular, and Circuit Features in Anxiety
Neuroscience Bulletin (2023)
-
nNOS and Neurological, Neuropsychiatric Disorders: A 20-Year Story
Neuroscience Bulletin (2023)
-
Targeting PSD95/nNOS by ZL006 alleviates social isolation-induced heightened attack behavior in mice
Psychopharmacology (2022)